Spatially segregated APOE+ macrophages restrict immunotherapy efficacy in clear cell renal cell carcinoma

Apr 30, 2025Theranostics

APOE-positive immune cells in different tumor areas may limit immunotherapy success in clear cell kidney cancer

AI simplified

Abstract

Elevated presence of Apolipoprotein E (APOE) macrophages in immune checkpoint blockade (ICB)-resistant clear cell renal cell carcinoma (ccRCC) is associated with shorter prognosis and worse response to treatment (< 0.001).

  • APOE macrophages are more prevalent in tumors resistant to ICB therapy compared to responsive ones.
  • Higher proportions of APOE macrophages correlate with poorer prognosis and diminished ICB efficacy.
  • Increased expression of CCAAT Enhancer Binding Protein Delta (CEBPD) is linked to enhanced immunosuppressive pathways that impede T cell recruitment.
  • Secreted Phosphoprotein 1 (SPP1) promotes proliferation and migration of ccRCC cells and recruits APOE macrophages to tumor margins.
  • APOE macrophages contribute to an immunosuppressive tumor microenvironment by releasing TGF-β, which limits the activity of anti-tumor T cells.

AI simplified

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free